Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04380324 · ClinicalTrials.gov registry record · Phase 1
A Study of NKTR-358 (LY3471851) in Healthy Participants
A Phase 1 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT04380324: Completed Phase 1 study, sponsored by Nektar Therapeutics.
NCT04380324 is a Phase 1 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 100 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04380324, a Phase 1 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in healthy participants. The study will last about 50 days for each participant.
Primary Outcome
Number of Participants with One or More SAEs Considered by the Investigator to be Related to Study Drug Administration
Interventions
- DRUG Placebo
- DRUG LY3471851
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-03-19 |
| Est. Completion | 2019-01-20 |
| Phase | Phase 1 |
What the finished NCT04380324 record still lists
NCT04380324 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04380324 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04380324 about?
NCT04380324 is a clinical study titled "A Study of NKTR-358 (LY3471851) in Healthy Participants". The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in healthy participants. The study will last about 50 days for each participant.
What is the current status of trial NCT04380324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2017-03-19. Estimated completion is 2019-01-20.
What interventions are being tested in trial NCT04380324?
The interventions under investigation include: Placebo (DRUG), LY3471851 (DRUG).
Who is sponsoring clinical trial NCT04380324?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04380324's enrollment target sits among peer trials
100 546th of 2000 higher than 1,411 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI